Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AB680 + Irinotecan + Leucovorin + Oxaliplatin + Zimberelimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AB680||AB-680|AB 680|quemliclustat||Adenosine Targeting 23 CD73 Antibody 11||AB680 is an inhibitor that selectively targets CD73, resulting in decreased production of extracellular adenosine (ADO), and potentially leading to decreased ADO-mediated T-cell suppression and improved anti-tumor immunity (Cancer Res 2018;78(13 Suppl):Abstract nr 1756, PMID: 32614585).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Leucovorin||Wellcovorin||Calcium folinate|Calcium citrovorum factor|folinic acid||Chemotherapy - Antimetabolite 14||Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554).|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 7||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Zimberelimab||GLS-010|AB122|AB-122|GLS010||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05688215||Phase Ib/II||AB680 + Irinotecan + Leucovorin + Oxaliplatin + Zimberelimab||Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma||Recruiting||USA||0|